Influence of age, gender, previous SARS-CoV-2 infection, and pre-existing diseases in antibody response after COVID-19 vaccination: A review

[1]  M. Kogevinas,et al.  SARS-CoV-2 infection, vaccination, and antibody response trajectories in adults: a cohort study in Catalonia , 2022, BMC Medicine.

[2]  T. Bourlet,et al.  Role of the humoral immune response during COVID-19: guilty or not guilty? , 2022, Mucosal Immunology.

[3]  M. Guarino,et al.  Humoral response to 2-dose BNT162b2 mRNA vaccine for Covid-19 in liver transplant recipients , 2022, Digestive and Liver Disease.

[4]  E. Duarte-Escalante,et al.  Vaccines Against COVID-19: A Review , 2022, Vaccines.

[5]  M. Fonseca,et al.  Dynamics of antibody response to CoronaVac vaccine , 2022, Journal of medical virology.

[6]  A. Botezatu,et al.  Kinetics and persistence of cellular and humoral immune responses to SARS‐CoV‐2 vaccine in healthcare workers with or without prior COVID‐19 , 2022, Journal of cellular and molecular medicine.

[7]  M. Guarino,et al.  Humoral Response to 2-dose BNT162b2 mRNA COVID-19 Vaccination in Liver Transplant Recipients , 2022, Clinical Gastroenterology and Hepatology.

[8]  A. Trkola,et al.  Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation , 2022, Transplantation and Cellular Therapy.

[9]  F. Zepp,et al.  Principles in Immunology for the Design and Development of Vaccines. , 2021, Methods in molecular biology.

[10]  A. Dębska-Ślizień,et al.  Boosting Humoral Immunity from mRNA COVID-19 Vaccines in Kidney Transplant Recipients , 2021, Vaccines.

[11]  J. Demengeot,et al.  Longitudinal Analysis of Antibody Responses to the mRNA BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis: A 6-Month Follow-Up , 2021, Frontiers in Medicine.

[12]  A. Vestri,et al.  Pfizer-BioNTech COVID-19 Vaccine in Gynecologic Oncology Patients: A Prospective Cohort Study , 2021, Vaccines.

[13]  S. Raghav,et al.  Persistence of Antibodies Against Spike Glycoprotein of SARS-CoV-2 in Healthcare Workers Post Double Dose of BBV-152 and AZD1222 Vaccines , 2021, Frontiers in Medicine.

[14]  G. Chertow,et al.  SARS-CoV-2 Vaccine Antibody Response and Breakthrough Infection in Patients Receiving Dialysis , 2021, Annals of Internal Medicine.

[15]  M. Mulligan,et al.  Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals , 2021, Science Translational Medicine.

[16]  G. Markopoulos,et al.  The Humoral Immune Response to BNT162b2 Vaccine Is Associated With Circulating CD19+ B Lymphocytes and the Naïve CD45RA to Memory CD45RO CD4+ T Helper Cells Ratio in Hemodialysis Patients and Kidney Transplant Recipients , 2021, Frontiers in Immunology.

[17]  Waleed H. Mahallawi,et al.  Effectiveness of COVID-19 Vaccines in Patients Under Maintenance Hemodialysis , 2021, Risk management and healthcare policy.

[18]  S. Kym,et al.  Antibody response to second dose of the BNT162b2 mRNA vaccine in the first 12 weeks in South Korea: A prospective longitudinal study , 2021, Vaccine.

[19]  A. Dębska-Ślizień,et al.  Significant humoral response to mRNA COVID-19 vaccine in kidney transplant recipients with prior exposure to SARS-CoV-2. The COViNEPH Project. , 2021, Polish archives of internal medicine.

[20]  D. McGovern,et al.  Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer , 2021, Cancer Research.

[21]  A. Trkola,et al.  Antibody Response to Sars-Cov-2 Vaccination in Patients Following Allogeneic Hematopoietic Cell Transplantation , 2021, Blood.

[22]  E. Vicaut,et al.  Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses , 2021, Journal of Thoracic Oncology.

[23]  S. Pradhan,et al.  Waning of Anti-spike Antibodies in AZD1222 (ChAdOx1) Vaccinated Healthcare Providers: A Prospective Longitudinal Study , 2021, Cureus.

[24]  G. Can,et al.  Inactive SARS-CoV-2 vaccine generates high antibody responses in healthcare workers with and without prior infection , 2021, Vaccine.

[25]  C. Solano,et al.  SARS‐CoV‐2‐reactive antibody detection after SARS‐CoV‐2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group , 2021, American journal of hematology.

[26]  Yong Lin,et al.  Characterization of SARS-CoV-2-specific humoral immunity and its potential applications and therapeutic prospects , 2021, Cellular & Molecular Immunology.

[27]  T. Bachelet,et al.  Humoral response after SARS-CoV-2 mRNA vaccines in dialysis patients: Integrating anti-SARS-CoV-2 Spike-Protein-RBD antibody monitoring to manage dialysis centers in pandemic times , 2021, PloS one.

[28]  M. Zeier,et al.  Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks , 2021, Vaccines.

[29]  F. Hakim,et al.  COVID-19 vaccine – Long term immune decline and breakthrough infections , 2021, Vaccine.

[30]  M. Montico,et al.  IgG antibodies against SARS-CoV-2 decay but persist 4 months after vaccination in a cohort of healthcare workers , 2021, Clinica Chimica Acta.

[31]  A. Dębska-Ślizień,et al.  Predictors of Humoral Response to mRNA COVID19 Vaccines in Kidney Transplant Recipients: A Longitudinal Study—The COViNEPH Project , 2021, Vaccines.

[32]  B. LaFleur,et al.  Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors , 2021, Nature Medicine.

[33]  P. Díaz,et al.  The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity , 2021, Frontiers in Immunology.

[34]  G. Fountzilas,et al.  Responses to SARS-CoV-2 Vaccination in Patients with Cancer (ReCOVer Study): A Prospective Cohort Study of the Hellenic Cooperative Oncology Group , 2021, Cancers.

[35]  J. Muñóz-Valle,et al.  Neutralizing Antibodies against SARS-CoV-2, Anti-Ad5 Antibodies, and Reactogenicity in Response to Ad5-nCoV (CanSino Biologics) Vaccine in Individuals with and without Prior SARS-CoV-2 , 2021, Vaccines.

[36]  F. Baldanti,et al.  Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study , 2021, Clinical Microbiology and Infection.

[37]  Jia Liu,et al.  Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting , 2021, Frontiers in Immunology.

[38]  N. Glaichenhaus,et al.  Safety and Cross-Variant Immunogenicity of a Three-dose COVID-19 mRNA Vaccine Regimen in Kidney Transplant Recipients , 2021, EBioMedicine.

[39]  M. Takemura,et al.  Antibody responses to BNT162b2 vaccination in Japan: Monitoring vaccine efficacy by measuring IgG antibodies against the receptor binding domain of SARS-CoV-2 , 2021, medRxiv.

[40]  D. Stuart,et al.  Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom , 2021, Nature Microbiology.

[41]  B. Mustanski,et al.  Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected individuals. , 2021, EClinicalMedicine.

[42]  A. Huppert,et al.  BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers , 2021, The Lancet Respiratory Medicine.

[43]  S. Fourati,et al.  Antibody response after second BNT162b2 dose in allogeneic HSCT recipients , 2021, The Lancet.

[44]  F. Hernandez-Ilizaliturri,et al.  Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies , 2021, Blood.

[45]  O. Yang,et al.  Primary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses. , 2021, ACS nano.

[46]  M. Drayson,et al.  COVID-19: Seroprevalence and Vaccine Responses in UK Dental Care Professionals , 2021, Journal of dental research.

[47]  H. Demirbakan,et al.  Quantitation of antibodies against SARS‐CoV‐2 spike protein after two doses of CoronaVac in healthcare workers , 2021, Journal of medical virology.

[48]  V. Munster,et al.  SARS-CoV-2 vaccines: anamnestic response in previously infected recipients , 2021, Cell Research.

[49]  G. Ciliberto,et al.  Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution , 2021, Journal of Hematology & Oncology.

[50]  B. Chain,et al.  Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose , 2021, Science.

[51]  A. Sattler,et al.  Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis , 2021, Frontiers in Immunology.

[52]  Aaron M. Rosenfeld,et al.  Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination , 2021, Science Immunology.

[53]  A. Kribben,et al.  Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis , 2021, Vaccines.

[54]  J. V. Van Eyk,et al.  Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2 , 2021, Nature Medicine.

[55]  L. Stamatatos,et al.  mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection , 2021, Science.

[56]  F. Pottoo,et al.  Targets and strategies for vaccine development against SARS-CoV-2 , 2021, Biomedicine & Pharmacotherapy.

[57]  Shubhabrata Mukherjee,et al.  Is COVID-19 Gender-sensitive? , 2021, Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology.

[58]  K. Chapin,et al.  Heterogeneous Longitudinal Antibody Responses to Covid-19 mRNA Vaccination , 2021, Clinical pathology.

[59]  A. Vacca,et al.  Actors on the Scene: Immune Cells in the Myeloma Niche , 2020, Frontiers in Oncology.

[60]  Zhènglì Shí,et al.  Characteristics of SARS-CoV-2 and COVID-19 , 2020, Nature Reviews Microbiology.

[61]  M. Gromiha,et al.  COVID-19 outbreak: history, mechanism, transmission, structural studies and therapeutics , 2020, Infection.

[62]  O. Franco,et al.  COVID-19 in Healthcare Workers: A Living Systematic Review and Meta-analysis of Prevalence, Risk Factors, Clinical Characteristics, and Outcomes , 2020, American journal of epidemiology.

[63]  Barney S. Graham,et al.  Rapid COVID-19 vaccine development , 2020, Science.

[64]  J. Blay,et al.  Lower detection rates of SARS-COV2 antibodies in cancer patients versus health care workers after symptomatic COVID-19 , 2020, Annals of Oncology.

[65]  Hyeshik Chang,et al.  The Architecture of SARS-CoV-2 Transcriptome , 2020, Cell.

[66]  E. Holmes,et al.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding , 2020, The Lancet.

[67]  Tiantian Han,et al.  Coronavirus infections and immune responses , 2020, Journal of medical virology.

[68]  N. Messina,et al.  The impact of vaccines on heterologous adaptive immunity. , 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[69]  R. Kennedy,et al.  Immunosenescence and human vaccine immune responses , 2019, Immunity & Ageing.

[70]  N. Hacohen,et al.  PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance , 2019, Nature Immunology.

[71]  S. Klein,et al.  Sex-based differences in immune function and responses to vaccination. , 2015, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[72]  M. Unruh,et al.  Immunization in End‐Stage Renal Disease: Opportunity to Improve Outcomes , 2013, Seminars in dialysis.

[73]  D. Abramowicz,et al.  Influenza A/H1N1 vaccine in patients treated by kidney transplant or dialysis: a cohort study. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[74]  Andrew Pekosz,et al.  The Xs and Y of immune responses to viral vaccines. , 2010, The Lancet. Infectious diseases.

[75]  Lieping Chen,et al.  PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells , 2010, Nature Immunology.

[76]  V. Preedy,et al.  Prospective Cohort Study , 2010 .

[77]  E. Fish.  The X-files in immunity: sex-based differences predispose immune responses , 2008, Nature Reviews Immunology.

[78]  I. Cook.  Sexual dimorphism of humoral immunity with human vaccines. , 2008, Vaccine.

[79]  R. Webster,et al.  The Antibody Response , 2008 .

[80]  G. Kobinger,et al.  Efficacy of severe acute respiratory syndrome vaccine based on a nonhuman primate adenovirus in the presence of immunity against human adenovirus. , 2006, Human gene therapy.

[81]  R. Peces,et al.  Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in hemodialysis patients. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[82]  D. Sommers,et al.  A longitudinal analysis , 1992 .

[83]  M. Buti,et al.  Long-term immunogenicity and efficacy of hepatitis B vaccine in hemodialysis patients. , 1992, American journal of nephrology.

[84]  A. Coutinho,et al.  Role of the humoral immune response in resistance to Theiler's virus infection , 1991, Journal of virology.